Inhaled fosamprenavir for laryngopharyngeal reflux: Toxicology and fluid dynamics modeling.
Journal Information
Full Title: Laryngoscope Investig Otolaryngol
Abbreviation: Laryngoscope Investig Otolaryngol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Otorhinolaryngology
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"data s1: in vivo toxicology aerosolization methods."
"CONFLICT OF INTEREST STATEMENT N.J. is a co‐founder, Chief Scientific Officer, and an investor in N‐Zyme Biomedical. N.J. is an inventor on International Patent Application PCT/US2021/027758, Aerosolized formulations of HIV protease inhibitors for the treatment of airway reflux, filed on April 16, 2021, and International Patent Application: PCT/US2023/071204, Sustained‐release oral fosamprenavir for the treatment of reflux, filed on July 28, 2023. T.S. is an investor in N‐Zyme Biomedical. Other authors have no financial relationships or conflicts of interest to disclose."
"FUNDING INFORMATION This work was funded by the Dr. Ralph and Marian Falk Medical Research Trust of the Bank of America, N‐Zyme Biomedical Inc., and the Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee, WI, USA."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025